Leiden Early Drug Discovery & Development
Leiden Early Drug Discovery & Development (LED3) is a multidisciplinary research network at Leiden University dedicated to advancing innovative approaches in early drug discovery and development. The initiative brings together 58 principal investigators from four institutes—the Institute of Biology Leiden (IBL), Leiden Academic Centre for Drug Research (LACDR), Leiden Institute of Advanced Computer Science (LIACS), and Leiden Institute of Chemistry (LIC), supported by the university’s technology transfer office LURIS.
Together, the network represents more than 250 researchers and staff with expertise spanning artificial intelligence, medicinal chemistry, molecular biology, pharmacology, metabolomics, structural biology, toxicology, and many other fields essential for modern drug discovery.
The vision of LED3 is to deepen our understanding of chemical and biological interactions at the molecular and cellular level to improve knowledge of human health and disease. By integrating diverse scientific disciplines, the network develops and applies novel concepts to enhance the efficiency and success of the drug discovery and development process. LED3 is intentionally target-, disease-, and therapeutic-area agnostic, enabling researchers to pursue transformative discoveries across a wide spectrum of biomedical challenges. The network also invests in advanced research infrastructure and promotes collaboration across disciplines while training the next generation of drug discovery scientists.
LED3’s scientific strength is reflected in its strong track record of competitive funding and collaborations. Researchers within the network have secured over 25 European Research Council (ERC) grants and multiple NWO VICI grants, and participate in major national initiatives such as Oncode Institute, Oncode Accelerator, PharmaNL, and several Gravitation programs. Collaborations extend locally with institutions such as LUMC and CHDR, nationally with research institutes and university medical centers, and internationally with industry partners including BioNTech, Johnson & Johnson, Roche, and DSM-Firmenich.
Beyond academia, LED3 generates tangible societal impact. The network has contributed to 14 spin-out companies and several translational successes, including compounds progressing through clinical development. Notable examples include Nizubaglustat®, currently in Phase 3 trials for rare metabolic disorders, and other therapeutic programs targeting diseases such as multiple sclerosis and cancer.
Through its collaborative ecosystem, cutting-edge facilities, and strong translational focus, LED3 serves as a hub for early drug discovery innovation in Leiden, connecting fundamental science with real-world therapeutic development.
